60
Participants
Start Date
May 23, 2023
Primary Completion Date
December 1, 2026
Study Completion Date
June 1, 2027
Lurbinectedin
Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
RECRUITING
Memorial Sloan Kettering, New York
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
Childrens National Hospital Michigan, Washington D.C.
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
Arthur M. Blank Hospital Children's Healthcare of Atlanta, Atlanta
RECRUITING
Johns Hopkins All Children's Hospital, St. Petersburg
RECRUITING
St. Jude Children's Research Hospital, Memphis
RECRUITING
Nationwide Childrens, Columbus
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
RECRUITING
Corewell Health, Grand Rapids
RECRUITING
UT Southwestern in Texas, Dallas
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Children's Hospital Los Angeles, Los Angeles
RECRUITING
Stanford Children's Health, Palo Alto
RECRUITING
The Hospital for Sick Children, Toronto
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY